Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.51 |
| ▸ | GBA1 | P04062 | 12/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130873 | 0.98 | SMPD1 (0.49) | SMPD1GBA1EPHX2KDM5C | |
| SCHEMBL6072137 | 0.93 | DPP4 (0.45) | SMPD1GBA1EPHX2KDM5C | |
| SCHEMBL6071691 | 0.86 | L3MBTL1 (0.50) | KDM5C | |
| SCHEMBL17427978 | 0.85 | DPP4 (0.44) | — | |
| SCHEMBL27978934 | 0.81 | DPP4 (0.46) | GBA1 | |
| SCHEMBL17396766 | 0.81 | ALDH1A1 (0.44) | — | |
| SCHEMBL616559 | 0.81 | SMPD1 (0.51) | SMPD1GBA1EPHX2 | |
| SCHEMBL23921581 | 0.80 | DPP4 (0.51) | — | |
| SCHEMBL6072289 | 0.79 | ALDH1A1 (0.45) | KDM5C | |
| SCHEMBL17396869 | 0.78 | GLS (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7795207-B2 | Lipopeptide compositions | MERLION PHARMACEUTICALS GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| EP-1951311-A1 | LIPOPEPTIDE COMPOSITIONS | Merlion Pharmaceuticals GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20070219124-A1 | Lipopeptide compositions | COMBINATURE BIOPHARM AG (DE) | 2007-09-20 | — | — | US | disclosed |
| WO-2007057005-A1 | LIPOPEPTIDE COMPOSITIONS | MERLION PHARMACEUTICALS GMBH (DE) | 2007-05-24 | — | — | WO | disclosed |
| CN-1839150-A | Lipopeptide antibacterial derivative composition and application method thereof | MIGENIX INC (CA) | 2006-09-27 | — | — | CN | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219124-A1 | Lipopeptide compositions | NOD2, IAPP, PTMS | SMPD1 317/4885GBA1 1192/4885EPHX2 3375/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | SMPD1 905/4885GBA1 1971/4885EPHX2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.